Ketamine by NRX Pharmaceuticals for Bipolar Disorder (Manic Depression): Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ketamine overview
Ketamine (NRX-100) is under development for the treatment of bipolar suicidal depression. The drug candidate is administered through intravenous route. It acts by targeting NMDA receptor.
NRX Pharmaceuticals overview
NRX Pharmaceuticals formerly Big Rock Partners Acquisition is a pharmaceutical company developing novel therapies for respiratory disorders. The company is headquartered in Wilmington, Delaware, the US.
For a complete picture of Ketamine’s drug-specific PTSR and LoA scores, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#Ketamine #NRX #Pharmaceuticals #Bipolar #Disorder #Manic #Depression #Likelihood #Approval
